Abstract
Sodium-glucose co-transporters are a family of glucose transporter found in the intestinal mucosa of the small intestine (SGLT-2) and the proximal tubule of the nephron (SGLT-1 and SGLT-2). They contribute to renal glucose reabsorption and most of renal glucose (about 90%) is reabsorbed by SGLT-2 located in the proximal renal tubule. Selectively inhibiting activity of SGLT-2 is an innovative therapeutic strategy for treatment of type 2 diabetes by enhancing urinary glucose excretion from the body. Therefore SGLT-2 inhibitors are considered to be potential antidiabetic drugs with an unique mechanism. This review will highlight some recent advances and structure-activity relationships in the discovery and development of SGLT-2 inhibitors including O-glycoside, C-glycoside, C, O-spiro glycoside and non glycosides.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Benzhydryl Compounds / chemical synthesis
-
Benzhydryl Compounds / chemistry
-
Benzhydryl Compounds / pharmacology
-
Diabetes Mellitus, Type 2 / drug therapy
-
Glucosides / chemical synthesis
-
Glucosides / chemistry
-
Glucosides / pharmacology
-
Glycosides
-
Humans
-
Hypoglycemic Agents / chemical synthesis*
-
Hypoglycemic Agents / chemistry
-
Hypoglycemic Agents / pharmacology
-
Molecular Structure
-
Monosaccharides / chemical synthesis*
-
Monosaccharides / chemistry
-
Monosaccharides / pharmacology
-
Sodium-Glucose Transporter 1 / metabolism
-
Sodium-Glucose Transporter 2 / metabolism*
-
Sodium-Glucose Transporter 2 Inhibitors*
-
Structure-Activity Relationship
Substances
-
Benzhydryl Compounds
-
C-glycoside
-
Glucosides
-
Glycosides
-
Hypoglycemic Agents
-
Monosaccharides
-
Sodium-Glucose Transporter 1
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors
-
dapagliflozin
-
6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol